Technical Analysis for KALV - KalVista Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 11.99 0.50% 0.06
KALV closed up 0.5 percent on Monday, March 18, 2024, on 65 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness 0.50%
Doji - Bullish? Reversal -3.54%
Stochastic Reached Oversold Weakness -3.54%
Oversold Stochastic Weakness -3.54%
Narrow Range Bar Range Contraction -4.00%
Inside Day Range Contraction -4.00%
MACD Bearish Centerline Cross Bearish -4.00%

   Recent Intraday Alerts

Alert Time
Up 3% about 15 hours ago
60 Minute Opening Range Breakout about 18 hours ago
Up 2% about 18 hours ago
Up 1% about 19 hours ago
Fell Below Previous Day's Low about 19 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

KalVista Pharmaceuticals, Inc. Description

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Disease Organ Systems Eye Enzymes Stage Pharmaceutical Macular Edema Diabetic Macular Edema Angioedema Hereditary Angioedema Kallikrein Complement Deficiency C1 Inhibitor Plasma Kallikrein Protease Inhibitor

Is KALV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 16.88
52 Week Low 6.255
Average Volume 862,066
200-Day Moving Average 10.70
50-Day Moving Average 13.68
20-Day Moving Average 13.33
10-Day Moving Average 13.12
Average True Range 0.86
RSI (14) 38.27
ADX 18.99
+DI 19.12
-DI 34.06
Chandelier Exit (Long, 3 ATRs) 14.30
Chandelier Exit (Short, 3 ATRs) 14.16
Upper Bollinger Bands 14.98
Lower Bollinger Band 11.69
Percent B (%b) 0.09
BandWidth 24.69
MACD Line -0.41
MACD Signal Line -0.16
MACD Histogram -0.2495
Fundamentals Value
Market Cap 414.36 Million
Num Shares 34.6 Million
EPS -3.03
Price-to-Earnings (P/E) Ratio -3.96
Price-to-Sales 107.42
Price-to-Book 4.83
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.15
Resistance 3 (R3) 13.14 12.74 12.95
Resistance 2 (R2) 12.74 12.45 12.75 12.89
Resistance 1 (R1) 12.37 12.27 12.56 12.38 12.82
Pivot Point 11.97 11.97 12.07 11.98 11.97
Support 1 (S1) 11.60 11.68 11.79 11.61 11.16
Support 2 (S2) 11.20 11.50 11.21 11.09
Support 3 (S3) 10.83 11.20 11.03
Support 4 (S4) 10.84